0000899243-19-004317.txt : 20190220
0000899243-19-004317.hdr.sgml : 20190220
20190220194832
ACCESSION NUMBER: 0000899243-19-004317
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181119
FILED AS OF DATE: 20190220
DATE AS OF CHANGE: 20190220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: El-Hibri Fuad
CENTRAL INDEX KEY: 0001380185
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33137
FILM NUMBER: 19620205
MAIL ADDRESS:
STREET 1: 2273 RESEARCH BLVD, SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Emergent BioSolutions Inc.
CENTRAL INDEX KEY: 0001367644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 141902018
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
BUSINESS PHONE: 240-631-3200
MAIL ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2018-11-19
2018-11-21
0
0001367644
Emergent BioSolutions Inc.
EBS
0001380185
El-Hibri Fuad
400 PROFESSIONAL DRIVE, SUITE 400
GAITHERSBURG
MD
20879
1
1
1
0
Chairman
Common Stock
2018-11-19
4
M
0
20000
14.44
A
1508675
D
Common Stock
2018-11-20
4
M
0
15173
14.44
A
1503848
D
Common Stock
2018-11-26
4
M
0
25000
13.38
A
1513675
D
Common Stock
2018-11-27
4
M
0
20832
13.38
A
1509507
D
Common Stock
2018-11-27
4
S
0
20832
69.59
D
1488675
D
Employee Stock Options (Right to Buy)
14.44
2018-11-19
4
M
0
20000
0.00
D
2019-03-12
Common Stock
20000
15173
D
Employee Stock Options (Right to Buy)
14.44
2018-11-20
4
M
0
15173
0.00
D
2019-03-12
Common Stock
15173
0
D
Employee Stock Options (Right to Buy)
13.38
2018-11-26
4
M
0
25000
0.00
D
2020-03-11
Common Stock
25000
20832
D
Employee Stock Options (Right to Buy)
13.38
2018-11-27
4
M
0
20832
0.00
D
2020-03-11
Common Stock
20832
0
D
All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission ("SEC") on November 21, 2018, which reported the sales of shares of the Issuer's common stock ("Common Stock") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises.
The number of shares of Common Stock directly beneficially owned by the Reporting Person reported on this amended Form 4 gives effect to the sales of Common Stock by the Reporting Person as reported on the Forms 4 filed with the SEC on November 21, 2018 and November 28, 2018, as applicable.
The reported option exercises were inadvertently omitted from the original Form 4 filed with the SEC on November 28, 2018, which reported the sales of shares of Common Stock only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.31 to $70.32.
The options vested in three equal installments on March 12, 2013, March 12, 2014 and March 12, 2015.
The options vested in three equal installments on March 11, 2014, March 11, 2015 and March 11, 2016.
/s/ Carl A. Valenstein, attorney-in-fact
2019-02-19